A Study to Learn About the Study Medicine (Called ARV-471) in People With ER+/HER2- Advanced BC in China
Status:
Not yet recruiting
Trial end date:
2024-12-09
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to learn about the pharmacokinetics. safety and
tolerability of the study medicine (called ARV-471) for the potential treatment of advanced
estrogen receptor postive and human epidermal growth factor receptor 2 negative breast
cancer.
This study is seeking participants have
- ER+/HER2- advanced breast cancer
- received at least 1 line of endocrine therapy with or without CDK4/6 inhibitor
- received up to 2 prior regimens of chemotherapy for advanced setting. All participants
in this study will receive ARV-471. ARV-471 will be given by mouth at home once a day.
The experiences of people receiving the study medicine will be examined. This will help
determine if the study medicine is safe and effective.
Participants will take part in this study until their cancer is no longer responding. During
this time, they will have visits at the study clinic about every 4 weeks.